Cell Therapeutics appeals FDA decision on pixantrone NDA for non-Hodgkin's lymphoma


USA-based Cell Therapeutics (Nasdaq and MTA: CTIC) says that it has submitted a formal appeal to the…

Cell TherapeuticsNorth AmericaOncologyPharmaceuticalpixantronePixuvirRegulation

EMEA validates Cell Therapeutics’ expanded pixantrone PIP


Seattle, USA-based Cell Therapeutics (CTI) says it has received notice that the European Medicines Agency…

Cell TherapeuticsEuropeNorth AmericaOncologyPharmaceuticalpixantronePixuvriRare diseasesRegulation

EU regulator approves Pfizer’s Lipitor for children; Cell Thera files pixantrone pediatric investigation plan with EMEA


The European Commission has approved a new chewable form of global drugs behemoth Pfizer’s Lipitor…

Cardio-vascularCell TherapeuticsEuropeLipitorOncologyPfizerPharmaceuticalpixantroneRare diseasesRegulationResearch

Italian medicines agency OKs NerPharMa facility to make Cell Therapeutics' pixantrone in EU


The Italian Medicines Agency (AIFA), the national authority responsible for drug regulation in Italy,…

Cell TherapeuticsOncologyPharmaceuticalpixantronePixuvriRegulation

US FDA calls for more info on Cell Thera’s pixantrone NDA, and firm says it will file for expanded access for NHL patients


Seattle, USA-based Cell Therapeutics revealed this morning that it had received a Complete Response Letter…

BiotechnologyCell TherapeuticsNorth AmericaOncologyPharmaceuticalpixantronePixuvriRegulation

Back to top